Skip Navigation LinksHome > Programmes (40) > STIs & HIV Research (17) > HPV Vaccine Study
    


HPV Vaccine Study 
Home > Programmes (40) > STIs & HIV Research (17) > HPV Vaccine Study
 

Project Focus
HPV infection

Project Location
Durban KwaZulu-Natal, South Africa

Duration of Project
2005 - 36 months

Project Partners
Cinicians and community members

Project Donors
MSD

Contact Details
Dr Arthi Ramkissoon

Project Aim/ Objectives
Aim
To evaluate the efficacy of quadrivalent HPV (Types 6, 11, 16, and 18) vaccine in reducing the incidence of  HPV 6-, 11-, 16-, and 18-related anogenital warts, and the incidence of HPV 6-, 11-, 16-, and 18-related genital infection in young men. 

Project Activities 

  • Recruitment, screening & enrolment of 24 participants.
  • Vaccination and post-vaccination follow-up for safety and efficacy for three years.
  • Regular ongoing HIV testing of participants

 

Anticipated/Actual Results
  • Vaccine - induced serum antibody responses to HPV 6, 11, 16, 18
  • Safety of dose regimen of quadrivalent HPV vaccine
  • Incidence of HPV related anogenital warts
  • Incidence of HPV 6, 11, 16, 18 detection/infection


Additional Outputs

  • Condom use and sexual risk behaviour in young men


Future Plans

  • none

 Projects in the STI's & HIV Research Cluster:
  A Multi Center Acute HIV-1 Infection Prospective Observational Cohort Study
  DfiD Research Programme Consortium: Consortium for Research and Capacity Building in Reproductive and Sexual Health and HIV/AIDS in developing countries
  A Safety & Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women (IPM011)
  Acute HIV infection (AHI) identification
  Contraceptive Research Planning Survey: Comparison of DEPO-PROVERA and IUD Pilot Study
  A phase III randomized, double blind, placebo controlled trial of acyclovir for the reduction of HIV acquisition among high risk HSV2+ HIV- individuals (HPTN039) (known locally as Thembalethu)
  Sub-study to an international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels for the prevention of vaginally acquired HPV infection
  A multi-centred randomised trial of therapeutic intervention at primary HIV-1 infection (also known as SPARTAC)
  An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels for the prevention of vaginally acquired HIV infection
  National Research Foundation Thuthuka Programme: Developing & Advancing Excellence in Researchers
  The Safety and feasibility study of the diaphragm used with Acidform gel or KY Jelly
  Evaluation of quadrivalent HPV vaccine in reducing the incidence of anogenital warts and related genital infection in young men
  IPM Microbicide Feasibility Study
  STI/HIV Research Adherence
  STI/HIV Research HSV2 Shedding
  STI/HIV Research Gates PIP
  Focus on Men: A Programme to Improve Male Involvement in Sexual & Reproductive Health (known locally as Mpilonhle-Mpilonde)